JP2013536871A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536871A5
JP2013536871A5 JP2013527348A JP2013527348A JP2013536871A5 JP 2013536871 A5 JP2013536871 A5 JP 2013536871A5 JP 2013527348 A JP2013527348 A JP 2013527348A JP 2013527348 A JP2013527348 A JP 2013527348A JP 2013536871 A5 JP2013536871 A5 JP 2013536871A5
Authority
JP
Japan
Prior art keywords
oxygen
compound according
optionally substituted
bond
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013527348A
Other languages
English (en)
Japanese (ja)
Other versions
JP6006211B2 (ja
JP2013536871A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/050393 external-priority patent/WO2012031237A1/en
Publication of JP2013536871A publication Critical patent/JP2013536871A/ja
Publication of JP2013536871A5 publication Critical patent/JP2013536871A5/ja
Application granted granted Critical
Publication of JP6006211B2 publication Critical patent/JP6006211B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013527348A 2010-09-02 2011-09-02 3員環の縮合エーテルカルバメートおよびその使用 Expired - Fee Related JP6006211B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37941410P 2010-09-02 2010-09-02
US61/379,414 2010-09-02
PCT/US2011/050393 WO2012031237A1 (en) 2010-09-02 2011-09-02 Fused tricyclic ether carbamates and their use

Publications (3)

Publication Number Publication Date
JP2013536871A JP2013536871A (ja) 2013-09-26
JP2013536871A5 true JP2013536871A5 (enExample) 2014-10-16
JP6006211B2 JP6006211B2 (ja) 2016-10-12

Family

ID=45773291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527348A Expired - Fee Related JP6006211B2 (ja) 2010-09-02 2011-09-02 3員環の縮合エーテルカルバメートおよびその使用

Country Status (5)

Country Link
US (2) US8563597B2 (enExample)
EP (1) EP2611295B1 (enExample)
JP (1) JP6006211B2 (enExample)
CA (1) CA2810005A1 (enExample)
WO (1) WO2012031237A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2810005A1 (en) 2010-09-02 2012-03-08 Purdue Research Foundation Fused tricyclic ether carbamates and their use
JP6622290B2 (ja) * 2014-05-16 2019-12-18 パーデュー・リサーチ・ファウンデーションPurdue Research Foundation Hiv−1プロテアーゼ阻害剤およびその用途
EP3538090B1 (en) * 2016-11-09 2022-06-22 Purdue Research Foundation Tricyclic p2-ligand containing hiv-protease inhibitors against hiv/aids
AR110922A1 (es) 2017-02-06 2019-05-15 Gilead Sciences Inc Compuestos inhibidores del vih
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
EP4121042A4 (en) * 2020-03-18 2024-04-17 Purdue Research Foundation Tricyclic p2-ligand containing potent hiv-protease inhibitors
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
CN100448444C (zh) * 2001-12-21 2009-01-07 泰博特克药品有限公司 含杂环取代苯基的磺酰胺广谱hiv蛋白酶抑制剂
EP2120562A4 (en) * 2006-11-21 2010-01-13 Purdue Research Foundation METHOD AND COMPOSITIONS FOR TREATING HIV INFECTIONS
EP2285216A4 (en) * 2008-02-21 2012-09-19 Sequoia Pharmaceuticals Inc HIV PROTEASE INHIBITOR AND COMBINED CYTOCHROME P450 INHIBITOR
CA2810005A1 (en) 2010-09-02 2012-03-08 Purdue Research Foundation Fused tricyclic ether carbamates and their use

Similar Documents

Publication Publication Date Title
JP2010527913A5 (enExample)
IL274901B2 (en) Substituted nucleosides, nucleotides and analogs thereof
JP2011219498A5 (enExample)
JP2012523457A5 (enExample)
JP2010511721A5 (enExample)
JP2013512915A5 (enExample)
JP2021513534A5 (enExample)
JP2017525730A5 (enExample)
JP2015500843A5 (enExample)
JP2015500885A5 (enExample)
JP2011529918A5 (enExample)
JP2008510828A5 (enExample)
JP2013515037A5 (enExample)
JP2009536660A5 (enExample)
JP2013525080A5 (enExample)
MY148636A (en) Benzimidazole derivatives
JP2012515776A5 (enExample)
JP2017533930A5 (enExample)
JP2011037841A5 (enExample)
JP2009500423A5 (enExample)
JP2014526533A5 (enExample)
JP2014510149A5 (enExample)
JP2012520247A5 (enExample)
JP2011513410A5 (enExample)
JP2007302689A5 (enExample)